Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × eribulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 103 Triple Negative Breast Neoplasms 23 Neoplasm Metastasis 17 Sarcoma 14 Neoplasms 14 Ovarian Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 5 Prostatic Neoplasms 4 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Urethral Neoplasms 2 Ureteral Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Lymphoma 2 Leiomyosarcoma 2 HER2-negative Breast Cancer 2 Colorectal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Salivary Gland Neoplasms 1 Relapsed Solid Tumors 1

Interventions

Fulvestrant 16 Letrozole 8 Anastrozole 7 Capecitabine 5 olaparib 4 Docetaxel 4 pyrotinib 3 palbociclib 3 Vinorelbine 3 Goserelin 3 Aromatase Inhibitors 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 exemestane 2 dalpiciclib 2 Trastuzumab 2 Paclitaxel 2 FCN-437c 2 Dasatinib 2 Alpelisib 2 vandetanib 1 talazoparib 1 sonidegib 1 neratinib 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 entinostat 1 elacestrant 1 disitamab vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05530057 2025-11-20

ESPERO

Seoul National University Hospital

Phase 2 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡